Advanced search
Publication Cover
OncoTargets and Therapy Volume 9, 2016 - Issue
Submit an article Journal homepage
37
Views
1
CrossRef citations to date
0
Altmetric
Original Research

A comparative study of idarubicin 12 mg/m2 and 8 mg/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients

Li ZhouDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
,
Xin LiuDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
,
Huilan LiuDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
,
Weibo ZhuDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
,
Xiaoyan CaiDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
,
Kaidi SongDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
,
Changcheng ZhengDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
,
Baolin TangDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of China
&
Zimin SunDepartment of Hematology, Anhui Provincial Hospital, Hefei, Anhui, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 985-991 | Published online: 29 Feb 2016

References

  • BermanEHellerGSantorsaJResults of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemiaBlood199177166616742015395
  • WiernikPHBanksPLCaseDCJrCytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemiaBlood1992793133191730080
  • PautasCMerabetFThomasXRandomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 studyJ Clin Oncol201028580881420048183
  • DohnerHEsteyEHAmadoriSEuropean LeukemiaNetDiagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood2010115345347419880497
  • O’DonnellMRAbboudCNAltmanJAcute myeloid leukemiaJ Natl Compr Canc Netw2012108984102122878824
  • MengFTWangYLLiuJZhaoJLiuRYZhouJNApoE genotypes are associated with age at natural menopause in Chinese femalesAge (Dordr)20123441023103221792545
  • RoweJTallmanMSIntensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?Blood1997906212121269310463
  • BishopJFMatthewsJPYoungGABradstockKLowenthalRMIntensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study GroupLeuk Lymphoma1998283–43153279517503
  • WeickJKKopeckyKJAppelbaumFRA randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group StudyBlood1996888284128518874180
  • WahlinABillstromRBjorOResults of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up studyEur J Haematol20098329910719385987
  • KoistinenPRatyRItalaMFinnish Leukaemia GroupLong-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia GroupEur J Haematol200778647748617391337
  • OhtakeSMiyawakiSFujitaHRandomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 studyBlood201111782358236520693429
  • CarellaAMCarlierPPungolinoEIdarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative GroupLeukemia1993721961998426473
  • PashkoSJacobsJSantorsaJThe cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemiaClin Ther19911333533601954636
  • FernandezHFSunZYaoXAnthracycline dose intensification in acute myeloid leukemiaN Engl J Med2009361131249125919776406
  • LöwenbergBOOssenkoppeleGJvan PuttenWDutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON)German AML Study Group (AMLSG)Swiss Group for Clinical Cancer Research (SAKK) Collaborative GroupHigh-dose daunorubicin in older patients with acute myeloid leukemiaN Engl J Med2009361131235124819776405
  • FlasshoveMMeusersPSchütteJLong-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemiaAnn Hematol2000791053354211100742
  • KobayashiTIchikawaMNannyaYKurokawaMThe effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemiaJpn J Clin Oncol201343101047105123956441

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.